FDA panel rejects ecstasy to treat PTSD
It cited flawed study data and the potential for abuse
![Dosage of MDMA in South Carolina](https://cdn.mos.cms.futurecdn.net/9odVXEkd4vZ5A6cta8zMZf-415-80.jpg)
What happened
A Food and Drug Administration advisory panel on Tuesday voted against approving the use of MDMA, a psychedelic drug commonly known as ecstasy or molly, to treat post-traumatic stress disorder. The committee voted 9-2 that data submitted by Lykos Therapeutics did not prove that MDMA combined with talk therapy was effective at treating PTSD.
Who said what
Panel members "praised the promise" of MDMA to treat PTSD, which hasn't seen a new drug in nearly 25 years, but "struggled with gaps in the research data" and the "potential for abuse," The Washington Post said. Lykos' two late-stage trials found vast improvements in a sizable majority of participants who got MDMA, but its data was "uncommonly messy," and the study participants were largely able to tell if they took a placebo or ecstasy, marring the results.
Lykos CEO Amy Emerson said the company is "disappointed in the vote" but will continue working with the FDA to meet the "urgent need for new, effective and accessible therapies" for the 13 million Americans living with PTSD.
What next?
The FDA expects to issue its final decision in mid-August.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
![https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516-320-80.jpg)
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
What will the presidential election mean for corporate taxes?
Today's Big Question Trump promises cuts. Biden said businesses should pay their 'fair share.'
By Joel Mathis, The Week US Published
-
'Making compensation more competitive with civilian careers is crucial'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
Infant deaths jumped in Texas after abortion ban
Speed Read Babies born in states with more abortion restrictions may be likelier to die within a year
By Peter Weber, The Week US Published
-
Infant deaths jumped in Texas after abortion ban
Speed Read Babies born in states with more abortion restrictions may be likelier to die within a year
By Peter Weber, The Week US Published
-
India's toxic alcohol problem
Under the Radar Bootleggers add lethal methanol to illegal liquor to cheaply increase potency, leading to widespread casualties
By Harriet Marsden, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published
-
Gene variant shows promise slowing Alzheimer's
Speed Read A rare genetic trait called Christchurch could delay the onset of disease
By Peter Weber, The Week US Published
-
Engineered stone is bad for the lungs
Under the Radar Quartz comes at a cost
By Devika Rao, The Week US Published
-
Why are girls starting puberty earlier?
In Depth Getting older, younger
By Devika Rao, The Week US Published
-
Cannabis tops alcohol in daily US consumption
Speed Read For the first time in U.S. history, daily cannabis users have outpaced daily drinkers
By Rafi Schwartz, The Week US Published
-
The push to ban decaf coffee
Under the radar Going caffeine-free can be risky
By Devika Rao, The Week US Published